Joakim Dillner
#114,045
Most Influential Person Now
Researcher
Joakim Dillner's AcademicInfluence.com Rankings
Joakim Dillnerbiology Degrees
Biology
#6504
World Rank
#9235
Historical Rank
Biotechnology
#59
World Rank
#60
Historical Rank
Genetics
#604
World Rank
#686
Historical Rank
Molecular Biology
#671
World Rank
#688
Historical Rank

Download Badge
Biology
Why Is Joakim Dillner Influential?
(Suggest an Edit or Addition)Joakim Dillner's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions (2007) (1755)
- Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials (2014) (1236)
- Human papillomavirus and Papanicolaou tests to screen for cervical cancer. (2007) (656)
- Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. (2008) (644)
- Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study (2008) (637)
- Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. (2001) (620)
- Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older (2009) (578)
- Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. (2006) (548)
- Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. (2010) (533)
- Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. (1999) (516)
- The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. (2009) (509)
- HPV Vaccination and the Risk of Invasive Cervical Cancer. (2020) (459)
- The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. (2009) (451)
- Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case‐control study in the Nordic countries (2004) (440)
- Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. (2001) (419)
- Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. (2001) (394)
- Should donors be allowed to give broad consent to future biobank research? (2006) (385)
- Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. (2008) (367)
- Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial (2010) (341)
- Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection (2000) (332)
- Strategies for global control of cervical cancer (1995) (327)
- Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. (2004) (323)
- A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions (2009) (321)
- Penile cancer: epidemiology, pathogenesis and prevention (2009) (311)
- An altered immune response to Epstein-Barr virus in multiple sclerosis (2004) (306)
- Chlamydia trachomatis infection as a risk factor for invasive cervical cancer (2000) (302)
- Etiology of Squamous Cell Carcinoma of the Penis (2000) (296)
- A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. (2013) (269)
- Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. (1996) (265)
- Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. (2009) (250)
- The serological response to papillomaviruses. (1999) (231)
- International standardization and classification of human papillomavirus types. (2015) (231)
- Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. (2005) (227)
- Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies (2006) (217)
- Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection (2009) (215)
- A population‐based prospective study of Chlamydia trachomatis infection and cervical carcinoma (2002) (195)
- Screening and cervical cancer cure: population based cohort study (2012) (193)
- High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study (2004) (191)
- European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination (2015) (191)
- HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. (2008) (190)
- Smoking as a major risk factor for cervical cancer and pre‐cancer: Results from the EPIC cohort (2014) (187)
- Are 20 human papillomavirus types causing cervical cancer? (2014) (186)
- Chlamydia trachomatis infection and persistence of human papillomavirus (2005) (179)
- Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma. (2007) (175)
- Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. (1996) (173)
- Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines (1987) (170)
- Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study (1996) (164)
- Epidemiology of Human Papillomavirus Infection (2000) (160)
- High prevalence of cutaneous human papillomavirus DNA on the top of skin tumors but not in "Stripped" biopsies from the same tumors. (2004) (156)
- Status of implementation and organization of cancer screening in The European Union Member States—Summary results from the second European screening report (2018) (155)
- HPV-FASTER: broadening the scope for prevention of HPV-related cancer (2016) (153)
- Modified General Primer PCR System for Sensitive Detection of Multiple Types of Oncogenic Human Papillomavirus (2009) (152)
- Stability over time of serum antibody levels to human papillomavirus type 16. (1998) (151)
- Seroepidemiology of the human polyomaviruses. (2003) (144)
- Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. (1997) (140)
- Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study (2013) (136)
- Cervical cancer screening in Europe: Quality assurance and organisation of programmes. (2015) (128)
- Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. (1999) (121)
- Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study (2002) (118)
- Global Proficiency Study of Human Papillomavirus Genotyping (2010) (118)
- Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial (2014) (116)
- ICTV Virus Taxonomy Profile: Papillomaviridae (2018) (116)
- The Epstein-Barr virus proteins. (1988) (113)
- Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. (1996) (112)
- Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate (2009) (112)
- Immunity to oncogenic human papillomaviruses. (2001) (111)
- Vaccination protects against invasive HPV‐associated cancers (2018) (111)
- Nordic biological specimen banks as basis for studies of cancer causes and control – more than 2 million sample donors, 25 million person years and 100 000 prospective cancers (2007) (110)
- Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. (2003) (110)
- Cervical Carcinoma and Sexual Behavior: Collaborative Reanalysis of Individual Data on 15,461 Women with Cervical Carcinoma and 29,164 Women without Cervical Carcinoma from 21 Epidemiological Studies (2009) (107)
- Circulating enterolactone and prostate cancer risk: A Nordic nested case‐control study (2002) (104)
- Epigenome-based cancer risk prediction: rationale, opportunities and challenges (2018) (104)
- Viral Load of Human Herpesvirus 8 in Peripheral Blood of Human Immunodeficiency Virus-Infected Patients with Kaposi's Sarcoma (2001) (102)
- Comparison of Development of Serum Antibodies to HPV16 and HPV33 and Acquisition of Cervical HPV DNA Among Sexually Experienced and Virginal Young Girls: A Longitudinal Cohort Study (1996) (102)
- A population-based five-year follow-up study of cervical human papillomavirus infection. (2000) (102)
- Nucleic acid tests for the detection of alpha human papillomaviruses. (2012) (101)
- Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the nordic countries. (2002) (101)
- The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort (2016) (101)
- Sero‐epidemiologal association between human‐papillomavirus infection and risk of prostate cancer (1998) (101)
- A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. (1997) (100)
- Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. (2008) (100)
- Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. (1999) (100)
- Cervical cancer screening in Sweden. (2000) (99)
- Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. (2007) (98)
- Maternal herpesvirus infections and risk of acute lymphoblastic leukemia in the offspring. (2003) (98)
- Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report (2018) (98)
- A population-based seroepidemiological study of cervical cancer. (1994) (97)
- Mapping of linear epitopes of human papillomavirus type 16: The E1, E2, E4, E5, E6 and E7 open reading frames (1990) (97)
- Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland (2007) (96)
- Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. (2014) (96)
- Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma (1995) (96)
- Different HLA‐DR‐DO haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type‐16 seropositive and seronegative Swedish women (1996) (95)
- Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. (1984) (94)
- Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. (1999) (93)
- HPV type-specific risks of high-grade CIN during 4 years of follow-up: A population-based prospective study (2007) (93)
- Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia (2011) (92)
- Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. (1986) (92)
- A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries (2018) (90)
- Deep sequencing extends the diversity of human papillomaviruses in human skin (2014) (90)
- Rate of Human Papillomavirus Clearance After Treatment of Cervical Intraepithelial Neoplasia (2002) (89)
- Ethical framework for previously collected biobank samples (2007) (88)
- Cutaneous human papillomaviruses persist on healthy skin. (2007) (88)
- Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. (2013) (88)
- No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11 (1999) (88)
- Population‐based type‐specific prevalence of high‐risk human papillomavirus infection in middle‐aged Swedish Women (2002) (86)
- Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. (2003) (86)
- Clinical trials of human papillomavirus vaccines and beyond (2015) (86)
- Prospective Seroepidemiologic Study of Human Papillomavirus and Other Risk Factors in Cervical Cancer (2011) (85)
- An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. (1986) (85)
- Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses (2013) (85)
- High throughput sequencing reveals diversity of Human Papillomaviruses in cutaneous lesions (2011) (84)
- A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. (1997) (84)
- Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers (1997) (82)
- Seroreactivity to Cutaneous Human Papillomaviruses among Patients with Nonmelanoma Skin Cancer or Benign Skin Lesions (2008) (82)
- Clinical trials of human papillomavirus vaccines and beyond (2013) (81)
- Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine (2015) (81)
- Virologic versus cytologic triage of women with equivocal Pap smears: A meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia (2004) (81)
- Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. (1999) (81)
- Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer (2006) (81)
- A synthetic peptide defines a serologic IgA response to a human papillomavirus-encoded nuclear antigen expressed in virus-carrying cervical neoplasia. (1989) (80)
- Recurrent Respiratory Papillomatosis: HPV Genotypes and Risk of High-Grade Laryngeal Neoplasia (2014) (78)
- Global Improvement in Genotyping of Human Papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study (2013) (78)
- Identification of human papillomavirus seroconversions. (1995) (76)
- Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. (2005) (75)
- Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. (2007) (74)
- Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. (2003) (73)
- The 2010 Global Proficiency Study of Human Papillomavirus Genotyping in Vaccinology (2012) (73)
- 2020 List of human papillomavirus assays Suitable for primary cervical cancer screening. (2021) (71)
- A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening (2006) (71)
- Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. (1999) (71)
- A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children (1999) (70)
- Translational Mini‐Review Series on Vaccines: Monitoring of human papillomavirus vaccination (2007) (70)
- Mapping of linear epitopes of human papillomavirus type 16: The L1 and L2 open reading frames (1990) (70)
- Combined effect of smoking and human papillomavirus type 16 infection in cervical carcinogenesis. (1998) (69)
- Prospective study of human papillomavirus and risk of cervical adenocarcinoma (2010) (69)
- Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses (2006) (69)
- ViraMiner: Deep learning on raw DNA sequences for identifying viral genomes in human samples (2019) (69)
- Metagenomic sequencing of "HPV-negative" condylomas detects novel putative HPV types. (2013) (68)
- Cancer risks after solid organ transplantation and after long‐term dialysis (2017) (68)
- Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. (2006) (68)
- Prospective Study of Human Papillomavirus (HPV) Types, HPV Persistence, and Risk of Squamous Cell Carcinoma of the Cervix (2010) (67)
- Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection (2008) (66)
- Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study (1999) (66)
- Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials (2017) (66)
- Assessing quality and functionality of DNA from fresh and archival dried blood spots and recommendations for quality control guidelines. (2007) (66)
- Interaction of Factors Related to the Metabolic Syndrome and Vitamin D on Risk of Prostate Cancer (2007) (65)
- Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening. (2013) (65)
- Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. (1998) (64)
- Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries (2020) (64)
- Monitoring of human papillomavirus vaccination (2011) (64)
- Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites (2003) (64)
- A prospective study on the risk of cervical intra‐epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears (1996) (63)
- Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV‐associated cancers (2008) (63)
- Unbiased Approach for Virus Detection in Skin Lesions (2013) (62)
- Dietary factors and in situ and invasive cervical cancer risk in the European prospective investigation into cancer and nutrition study (2011) (62)
- BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. (1988) (62)
- JC viral loads in patients with Crohn’s disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? (2008) (61)
- Cohort Profile: The Janus Serum Bank Cohort in Norway. (2016) (61)
- Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. (1995) (60)
- In Vivo and In Vitro Intragenomic Rearrangement of TT Viruses (2007) (60)
- Change in Population Prevalences of Human Papillomavirus after Initiation of Vaccination: The High-Throughput HPV Monitoring Study (2014) (60)
- Staphylococcus aureus and Squamous Cell Carcinoma of the Skin (2009) (59)
- Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. (2000) (59)
- Human Papillomavirus 16, 18, and 33 Infections and Risk of Prostate Cancer: A Nordic Nested Case-Control Study (2005) (59)
- Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom (2002) (59)
- Long‐term HPV type‐specific risks of high‐grade cervical intraepithelial lesions: A 14‐year follow‐up of a randomized primary HPV screening trial (2015) (58)
- Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: Basis for a virus‐like particle ELISA (2005) (57)
- Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays--an update. (2006) (57)
- Comparison between the Hybrid Capture II Test and a PCR-Based Human Papillomavirus Detection Method for Diagnosis and Posttreatment Follow-Up of Cervical Intraepithelial Neoplasia (2005) (57)
- Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA (1996) (56)
- Correlates of the spread of human papillomavirus infection. (2000) (56)
- Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. (2001) (56)
- Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis. (2008) (55)
- Alcohol, smoking and human papillomavirus in laryngeal carcinoma: a Nordic prospective multicenter study (2007) (55)
- Cancer Prevention Europe (2019) (55)
- Prospective study of human papillomavirus seropositivity and risk of nonmelanoma skin cancer. (2012) (55)
- SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study. (2020) (54)
- High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study (2018) (54)
- Human papillomavirus type 197 is commonly present in skin tumors (2015) (54)
- Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. (1995) (54)
- Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. (1990) (54)
- Human papillomavirus type‐specific persistence and recurrence after treatment for cervical dysplasia (2014) (53)
- A population-based cohort study of KIR genes and genotypes in relation to cervical intraepithelial neoplasia. (2005) (53)
- Antibodies to Merkel cell polyomavirus correlate to presence of viral DNA in the skin. (2011) (52)
- High-throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. (2008) (52)
- Molecular methods for identification and characterization of novel papillomaviruses. (2015) (52)
- Malignant epithelial tumors (2004) (51)
- Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development (2018) (51)
- Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC) (2020) (51)
- Genetic predisposition, parity, age at first childbirth and risk for breast cancer (2012) (51)
- Next generation sequencing for human papillomavirus genotyping. (2013) (50)
- Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. (1997) (50)
- Gender‐neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III) (2018) (50)
- Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969–1989 (1998) (50)
- Characterization of a second Epstein‐Barr virus‐determined nuclear antigen associated with the BamHI WYH region of EBV DNA (1985) (49)
- Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden. (2000) (49)
- Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses (1991) (49)
- High risk genital papillomavirus infections are not spread vertically (1999) (49)
- Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model (2012) (49)
- A Novel and Rapid PCR-Based Method for Genotyping Human Papillomaviruses in Clinical Samples (2000) (47)
- Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. (2016) (47)
- Serum and salivary IgA antibodies against a defined epitope of the Epstein‐Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma (1990) (47)
- Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: Evidence from the EPIC cohort (2014) (47)
- Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. (2002) (47)
- Lymphoblastoid cell lines and burkitt‐lymphoma‐derivee cell lines differ in the expression of a second epstein‐barr virus encoded nuclear antigen (1986) (47)
- Towards quality and order in human papillomavirus research. (2018) (47)
- Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study (2016) (46)
- Comparison of archival plasma and formalin-fixed paraffin-embedded tissue for genotyping in hepatocellular carcinoma. (2005) (46)
- Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. (1995) (46)
- Three novel papillomaviruses (HPV109, HPV112 and HPV114) and their presence in cutaneous and mucosal samples. (2010) (45)
- EUROGIN 2008 roadmap on cervical cancer prevention (2009) (45)
- Impact of gender‐neutral or girls‐only vaccination against human papillomavirus—Results of a community‐randomized clinical trial (I) (2018) (44)
- Endogenous steroid hormone levels in early pregnancy and risk of testicular cancer in the offspring: A nested case–referent study (2009) (44)
- Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. (2004) (44)
- Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser. (2000) (44)
- Infrastructure and Facilities for Human Biobanking in Low- and Middle-Income Countries: A Situation Analysis (2015) (44)
- Antibodies against synthetic peptides react with the second Epstein‐Barr virus‐associated nuclear antigen. (1985) (43)
- Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles. (2005) (43)
- Serological diagnosis of human polyomavirus infection. (2006) (43)
- A randomized trial of basing treatment on human papillomavirus and/or cytology results in low-grade cervical lesion triage. (2008) (43)
- Serum antibody response to the heat shock protein 60 of Chlamydia trachomatis in women with developing cervical cancer. (2003) (43)
- Multiplex Detection of Human Herpesviruses from Archival Specimens by Using Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (2007) (43)
- Primary human papillomavirus testing in organized cervical screening (2013) (42)
- The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study (2015) (42)
- Tumor necrosis factor A and MHC class I chain related gene A (MIC-A) polymorphisms in Swedish patients with cervical cancer. (2001) (42)
- European Code against Cancer 4th Edition: Infections and Cancer. (2015) (42)
- Management of women with human papillomavirus persistence: long‐term follow‐up of a randomized clinical trial (2017) (42)
- Targeting Human Papillomavirus to Reduce the Burden of Cervical, Vulvar and Vaginal Cancer and Pre-Invasive Neoplasia: Establishing the Baseline for Surveillance (2014) (42)
- A candidate CpG SNP approach identifies a breast cancer associated ESR1‐SNP (2011) (41)
- Seropositivity to human herpesvirus 8 in relation to sexual history and risk of sexually transmitted infections among women (2000) (41)
- Translational Cancer Research: Balancing Prevention and Treatment to Combat Cancer Globally (2014) (40)
- Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein. (1997) (40)
- Subtype HPV38b[FA125] demonstrates heterogeneity of human papillomavirus type 38 (2006) (40)
- No excess risk for colorectal cancer among subjects seropositive for the JC polyomavirus (2007) (40)
- Combined effect of low-penetrant SNPs on breast cancer risk (2011) (40)
- Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study (2022) (40)
- Endogenous Sex Steroids and Risk of Cervical Carcinoma: Results from the EPIC Study (2011) (40)
- Human papillomavirus genotypes in cervical cancers in Mozambique. (2004) (39)
- Randomised health services studies (2012) (38)
- Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. (2016) (38)
- Methylation in Predicting Progression of Untreated High-grade Cervical Intraepithelial Neoplasia (2019) (38)
- Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. (2006) (38)
- Chlamydial Antibodies and Risk of Prostate Cancer (2005) (38)
- A prospective study of the relationship between prediagnostic Human Papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas (2002) (37)
- Machine Learning for detection of viral sequences in human metagenomic datasets (2018) (37)
- Risk of invasive cervical cancer associated with polymorphic HLA DR/DQ haplotypes (2002) (37)
- No evidence of enteroviruses in the intestine of patients with type 1 diabetes (2012) (37)
- Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies—a prospective study (1993) (37)
- Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection. (2000) (37)
- Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. (1993) (37)
- Prospective Study of HPV16 Viral Load and Risk of In Situ and Invasive Squamous Cervical Cancer (2012) (37)
- Methods in Biobanking (2011) (36)
- No serological evidence of association between prostate cancer and infection with herpes simplex virus type 2 or human herpesvirus type 8: a nested case-control study. (2005) (36)
- Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer (2018) (36)
- Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden (2017) (36)
- Time for a European initiative for research to prevent cancer: A manifesto for Cancer Prevention Europe (CPE) (2018) (36)
- Activation of maternal Epstein-Barr virus infection and risk of acute leukemia in the offspring. (2006) (36)
- Cervical cytology biobanks as a resource for molecular epidemiology. (2011) (36)
- Population‐based study of screening test performance indices of three human papillomavirus DNA tests (2007) (36)
- Human papillomavirus type-specific risk of cervical cancer in a population with high human immunodeficiency virus prevalence: case-control study. (2011) (36)
- Evaluation of cost-precision rations of different strategies for ELISA measurement of serum antibody levels. (2002) (35)
- Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads. (2010) (35)
- Does human papillomavirus-negative condylomata exist? (2015) (35)
- Efficacy of HPV-based screening for prevention of invasive cervical cancer : Follow-up of four European randomized controlled trials (2014) (35)
- Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland (2013) (35)
- Induction of bovine papillomavirus E2 gene expression and early region transcription by cell growth arrest: correlation with viral DNA amplification and evidence for differential promoter induction (1990) (34)
- Male Circumcision and Serologically Determined Human Papillomavirus Infection in a Birth Cohort (2009) (34)
- Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine? (2004) (34)
- Risk of second cancers after the diagnosis of Merkel cell carcinoma in Scandinavia (2010) (34)
- A Nested Case-Control Study of Intrauterine Exposure to Persistent Organochlorine Pollutants and the Risk of Hypospadias (2012) (34)
- Structural analysis of the human papillomavirus type 16-E2 transactivator with antipeptide antibodies reveals a high mobility region linking the transactivation and the DNA-binding domains. (1991) (34)
- Cervical cancer case–control audit: Results from routine evaluation of a nationwide cervical screening program (2019) (33)
- Organization and quality of HPV vaccination programs in Europe. (2015) (33)
- Molecular and serological studies of human papillomavirus among patients with anal epidermoid carcinoma (1993) (33)
- Evaluation of HPV type‐replacement in unvaccinated and vaccinated adolescent females—Post‐hoc analysis of a community‐randomized clinical trial (II) (2018) (33)
- Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination (2000) (33)
- Eradication of human papillomavirus and elimination of HPV-related diseases – scientific basis for global public health policies (2019) (33)
- Diversity of human papillomaviruses in skin lesions. (2013) (33)
- Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. (2007) (32)
- Characterization of two novel cutaneous human papillomaviruses, HPV93 and HPV96. (2007) (32)
- The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus‐like particle vaccine in European women aged 16 to 24 (2009) (32)
- Herpes simplex virus and human papillomavirus in a population‐based case‐control study of cervical intraepithelial neoplasia grade II‐III (1998) (32)
- A population-based study of cervical carcinoma and HPV infection in Latvia. (2004) (32)
- Squamous Cell Carcinoma of the Penis: Premalignant Lesions (2000) (32)
- Seroepidemiology as basis for design of a human papillomavirus vaccination program. (2008) (32)
- Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. (2018) (32)
- No serological evidence for non-sexual spread of HPV16 (1994) (32)
- Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection (1995) (32)
- Antibodies against papillomavirus antigens in cervical secretions from condyloma patients (1993) (31)
- Continuing global improvement in human papillomavirus DNA genotyping services: The 2013 and 2014 HPV LabNet international proficiency studies. (2018) (31)
- The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium. (2018) (31)
- Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types. (2013) (31)
- HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1. (1995) (30)
- A prospective seroepidemiological study of human herpesvirus-8 infection and the risk of multiple myeloma (2001) (30)
- MICA gene polymorphism and the risk to develop cervical intraepithelial neoplasia. (1999) (30)
- Down‐regulation of the EBV‐encoded membrane protein (LMP) in burkitt lymphomas (1987) (30)
- Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women. (2019) (30)
- Laboratory Diagnosis of Human Herpesvirus 8 Infection in Humans (2002) (30)
- Performance of Commercial Reverse Line Blot Assays for Human Papillomavirus Genotyping (2012) (30)
- Interactions Between High- and Low-Risk HPV Types Reduce the Risk of Squamous Cervical Cancer. (2015) (29)
- Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort (2018) (29)
- Re: Have we resolved how to triage equivocal cervical cytology? (2004) (29)
- Maternal human polyomavirus infection and risk of neuroblastoma in the child (2005) (29)
- Ensuring quality in studies linking cancer registries and biobanks (2010) (29)
- Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection. (1998) (29)
- Detection of DNA viruses in prostate cancer (2016) (29)
- H. pylori Seropositivity before Age 40 and Subsequent Risk of Stomach Cancer: A Glimpse of the True Relationship? (2011) (28)
- Human serum antibodies to a major defined epitope of human herpesvirus 8 small viral capsid antigen. (1999) (28)
- International collaborative proficiency study of Human Papillomavirus type 16 serology. (2012) (28)
- Epidemiology of Kaposi's Sarcoma herpesvirus (HHV8) in Västerbotten county, Sweden (2006) (27)
- Type-Specific Human Papillomavirus Biological Features: Validated Model-Based Estimates (2013) (27)
- High-Throughput Monitoring of Human Papillomavirus Type Distribution (2012) (26)
- Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR (2020) (26)
- Impact of HPV vaccination on cervical screening performance: a population-based cohort study (2020) (26)
- Prospective study of Merkel cell polyomavirus and risk of Merkel cell carcinoma (2014) (26)
- The Bcl‐xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma (2009) (26)
- Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors (1991) (26)
- HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses. (2004) (26)
- Nuclear DNA-binding proteins determined by the Epstein-Barr virus-related simian lymphotropic herpesviruses H. gorilla, H. pan, H. pongo and H. papio. (1987) (26)
- Validation of a standardized extraction method for formalin-fixed paraffin-embedded tissue samples. (2016) (26)
- Phylogenetically diverse TT virus viremia among pregnant women. (2012) (25)
- Introduction of human papillomavirus (HPV) vaccination in Sweden. (2009) (25)
- The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes. (1995) (25)
- Human papillomavirus antibody responses among patients with incident cervical carcinoma (1997) (25)
- Vaginal self-sampling without preservative for human papillomavirus testing shows good sensitivity. (2013) (24)
- Maternal smoking during pregnancy and testicular cancer in the sons: a nested case-control study and a meta-analysis. (2009) (24)
- Joint Nordic prospective study on human herpesvirus 8 and multiple myeloma risk (2005) (24)
- Order of HPV/Chlamydia infections and cervical high‐grade precancer risk: A case‐cohort study (2013) (24)
- The Swedish cervical cytology biobank: sample handling and storage process. (2013) (24)
- Bereavement Is Associated with an Increased Risk of HPV Infection and Cervical Cancer: An Epidemiological Study in Sweden. (2016) (24)
- Registry-based assessment of the status of cervical screening in Sweden (2016) (24)
- Prospective study of genital human papillomaviruses and nonmelanoma skin cancer (2013) (24)
- Cost‐effectiveness of primary cytology and HPV DNA cervical screening (2008) (24)
- Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme (2014) (24)
- Increasing participation in cervical screening by targeting long‐term nonattenders: Randomized health services study (2019) (24)
- A population‐based case‐control study of human papillomavirus‐type‐16 seropositivity and incident high‐grade dysplasia of the uterine cervix (1996) (23)
- Extension of the viral ecology in humans using viral profile hidden Markov models (2018) (23)
- A population-based study of human papillomavirus deoxyribonucleic acid testing for predicting cervical intraepithelial neoplasia. (1998) (23)
- Correction: The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort (2016) (23)
- Low levels of serum vitamins A and E in blood and subsequent risk for cervical cancer: interaction with HPV seropositivity. (1999) (23)
- Maternal Epstein‐Barr virus and cytomegalovirus infections and risk of testicular cancer in the offspring: a nested case‐control study (2008) (23)
- Serology of human papillomavirus (1995) (23)
- Seropositivity to Multiple Sexually Transmitted Infections Is Not Common (2000) (23)
- Levels of immunoglobulin G antibodies against defined epitopes of the L1 and L2 capsid proteins of human papillomavirus type 6 are elevated in men with a history of condylomata acuminata (1992) (23)
- Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11. (2003) (23)
- Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study (2017) (22)
- Infection with Parvovirus B19 and Herpes viruses in early pregnancy and risk of second trimester miscarriage or very preterm birth. (2008) (22)
- Scanning the structure and antigenicity of HPV-16 E6 and E7 oncoproteins using antipeptide antibodies. (1994) (22)
- Malignant epithelial tumours (2006) (22)
- Prevention of human papillomavirus-associated cancers. (2015) (22)
- Patterns of Human Papillomavirus Types in Multiple Infections: An Analysis in Women and Men of the High Throughput Human Papillomavirus Monitoring Study (2013) (22)
- Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2 (2021) (21)
- Serological responses to papillomavirus group-specific antigens in women with neoplasia of the cervix uteri (1990) (21)
- HPV‐mRNA and HPV‐DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri (2018) (21)
- Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied (2020) (21)
- Characterization of the complete genomes of Camelus dromedarius papillomavirus types 1 and 2. (2011) (21)
- Occurrence of human papillomavirus (HPV) type replacement by sexual risk‐taking behaviour group: Post‐hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV) (2019) (21)
- Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56–60 (2017) (21)
- Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers (2021) (21)
- Risk of high-grade lesions after atypical glandular cells in cervical screening: a population-based cohort study (2017) (20)
- Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model (2014) (20)
- Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance Serology (2012) (20)
- High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders (2017) (20)
- Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron) (2021) (20)
- Systematic evaluation of SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay (2021) (20)
- Preventive human papillomavirus vaccination (2002) (20)
- Benefits of catch‐up in vaccination against human papillomavirus in medium‐ and low‐income countries (2013) (20)
- Cellular and humoral immune responses to synthetic peptides deduced from the amino‐acid sequences of Epstein‐Barr virus‐encoded proteins in EBV‐transformed cells (1987) (20)
- Genotyping of human papillomavirus in triaging of low-grade cervical cytology. (2011) (20)
- Predominance of serum antibodies to synthetic peptide stemming from HPV 18 open reading frame E2 in cervical adenocarcinoma. (1992) (19)
- Viruses in cancers among the immunosuppressed (2017) (19)
- The interface of population-based cancer registries and biobanks in etiological and clinical research – current and future perspectives (2010) (19)
- Randomized healthservices study of human papillomavirus‐based management of low‐grade cytological abnormalities (2011) (19)
- Invitation strategies and coverage in the population-based cancer screening programmes in the European Union (2019) (19)
- Cervical screening and risk of adenosquamous and rare histological types of invasive cervical carcinoma: population based nested case-control study (2019) (19)
- Sound implementation of human papillomavirus vaccination as a community-randomized trial (2008) (19)
- The Epstein‐Barr virus determined nuclear antigen is composed of at least three different anitgens (1986) (18)
- Follow‐up of women with cervical cytological abnormalities showing atypical squamous cells of undetermined significance or low‐grade squamous intraepithelial lesion: a nationwide cohort study (2017) (18)
- Long‐term HPV type‐specific risks for ASCUS and LSIL: A 14‐year follow‐up of a randomized primary HPV screening trial (2015) (18)
- Cutaneous Human Papillomaviruses and Squamous Cell Carcinoma of the Skin: Nested Case–Control Study (2016) (18)
- No Risk of Maternal EBV Infection for Childhood Leukemia (2009) (18)
- Chlamydia trachomatis Strain Types Have Diversified Regionally and Globally with Evidence for Recombination across Geographic Divides (2017) (18)
- Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Serum as Predictor of Severe Outcome in Coronavirus Disease 2019: A Retrospective Cohort Study (2020) (17)
- Laboratory audit as part of the quality assessment of a primary HPV-screening program. (2016) (17)
- Disappearance of antibodies to HPV 16 E7 after treatment for cervical cancer (1993) (17)
- Purification and characterization of the epstein‐barr virus nuclear antigen 2 using monoclonal antipeptide antibodies (1988) (17)
- Human papillomavirus subtypes are not uncommon. (2007) (17)
- Moderate variation of the oncogenic potential among high‐risk human papillomavirus types in gynecologic patients with cervical abnormalities (2003) (16)
- Patients would benefit from simplified ethical review and consent procedure. (2013) (16)
- Expressed Prostate Secretions in the Study of Human Papillomavirus Epidemiology in the Male (2013) (16)
- Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology. (2005) (16)
- Cutaneous human papillomavirus 88: Remarkable differences in viral load (2008) (16)
- Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study (2021) (16)
- Biobanks collected for routine healthcare purposes: build-up and use for epidemiologic research. (2011) (16)
- Metagenomic sequencing of expressed prostate secretions (2014) (16)
- Cervical cancer screening in Sweden 2014-2016 (2018) (16)
- The Janus Serum Bank-From sample collection to cancer research (2009) (16)
- Roadmap for a precision-medicine initiative in the Nordic region (2019) (16)
- Poor antibody response against human papillomavirus in adult-onset laryngeal papillomatosis. (2001) (15)
- Cervical cytology biobanking in Europe. (2010) (15)
- Salivary sIgA response in HIV-1 infection. (1999) (15)
- Methods for screening and diagnosis (2007) (15)
- A novel human in vitro papillomavirus type 16 positive tonsil cancer cell line with high sensitivity to radiation and cisplatin (2019) (15)
- ViraPipe: scalable parallel pipeline for viral metagenome analysis from next generation sequencing reads (2017) (14)
- The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples (2022) (14)
- Pre-vaccination seroprevalence of 15 human papillomavirus (HPV) types among women in the population-based Slovenian cervical screening program. (2013) (14)
- Risk stratification in cervical cancer screening by complete screening history: Applying bioinformatics to a general screening population (2017) (14)
- A prospective study of antibody responses to defined epitopes of human papillomavirus (HPV) type 16 in relationship to genital and anorectal presence of HPV DNA. (1994) (14)
- Primary screening for human papillomavirus infection. (2001) (13)
- HPV-16 transmission (1995) (13)
- Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program. (2020) (13)
- Serum p53 accumulation and altered antibody responses to Epstein‐Barr virus proteins precede diagnosis of haemopoietic malignancies of lymphoid origin (1996) (13)
- Seroprevalences of Antibodies to 11 Human Papillomavirus (HPV) Types Mark Cumulative HPV Exposure (2018) (13)
- Evaluation of serum antibody response to a newly identified B-cell epitope in the minor nucleocapsid protein L2 of human papillomavirus type 16. (1993) (13)
- A translational multiplex serology approach to profile the prevalence of anti-SARS-CoV-2 antibodies in home-sampled blood (2020) (13)
- De novo sequence assembly requires bioinformatic checking of chimeric sequences (2020) (13)
- Transcription of human papillomavirus oncogenes in head and neck squamous cell carcinomas. (2020) (12)
- Risk of invasive cervical cancer in relation to management of abnormal Pap smear results. (2009) (12)
- Clustering of Seropositivities for Sexually Transmitted Infections (2002) (12)
- Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. (2020) (12)
- Sequencing detects human papillomavirus in some apparently HPV-negative invasive cervical cancers. (2019) (12)
- A seroepidemiologic study of HPV infection and incident cervical squamous intraepithelial lesions. (1994) (12)
- No detection of SV40 DNA in mesothelioma tissues from a high incidence area in Sweden. (2007) (12)
- Viremia during pregnancy and risk of childhood leukemia and lymphomas in the offspring: Nested case–control study (2016) (12)
- Screening for nasopharyngeal carcinoma with an ELISA using the Epstein-Barr virus nuclear antigen, EBNA 1: a complementary test to the IgA/VCA immunofluorescence assay. (1993) (12)
- Long‐term follow‐up of human papillomavirus type replacement among young pregnant Finnish females before and after a community‐randomised HPV vaccination trial with moderate coverage (2020) (11)
- Seroepidemiology of human papillomavirus type 73: A sexually transmitted low‐risk virus (2000) (11)
- Cancer Registry follow‐up for 17 million person‐years of a nationwide maternity cohort (2017) (11)
- Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carcinoma of the uterine cervix (1995) (11)
- Differences in risk for SARS-CoV-2 infection among healthcare workers (2021) (11)
- Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care (2021) (11)
- Enzyme immunoassay detection of induction of MHC class I expression by synthetic peptides from the E6 and E7 regions of human papillomavirus type 16. (1994) (11)
- Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study (2019) (11)
- Absence of epstein–barr and cytomegalovirus infection in neuroblastoma cells by standard detection methodologies (2013) (11)
- How many Human Papillomavirus types do we need to screen for? (2020) (11)
- Decline of the new Swedish variant of Chlamydia trachomatis after introduction of appropriate testing (2012) (11)
- Antibodies against human papillomavirus type 6 capsids are elevated in men with previous condylomas (1997) (11)
- Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis (2022) (10)
- Are human papillomavirus DNA prevalences providing high-flying estimates of infection? An international survey of HPV detection on environmental surfaces (2013) (10)
- Molecular size variation of EBNA is determined by the EB viral genome. (1984) (10)
- Genome-wide transcriptome profiling of ex-vivo precision-cut slices from human pancreatic ductal adenocarcinoma (2020) (10)
- Erratum: The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: Results from the EPIC cohort (PLoS ONE (2016) 11:1 (e0147029) DOI:10.1371/journal.pone.0147029) (2016) (10)
- A summary of the 25th International Papillomavirus Conference 2009: vaccines, screening, epidemiology and therapeutics. (2010) (10)
- The Launch of an International Animal Papillomavirus Reference Center (2019) (10)
- A basis for translational cancer research on aetiology, pathogenesis and prognosis: Guideline for standardised and population-based linkages of biobanks to cancer registries. (2015) (10)
- [Cervical cancer has increased in Sweden in women who had a normal cell sample]. (2018) (10)
- Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia (2018) (10)
- Primary induction of human cytotoxic lymphocytes against a synthetic peptide of the human immunodeficiency virus type 1 protease. (1997) (10)
- Human papillomavirus types in cervical dysplasia among young HPV‐vaccinated women: Population‐based nested case–control study (2019) (10)
- A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) – Study protocol for a randomised controlled trial (2021) (10)
- Immunobiology of papillomavirus. Prospects for vaccination (1992) (10)
- Sustained Cross-Reactive Antibody Responses After Human Papillomavirus Vaccinations: Up To 12 Years Follow-Up In The Finnish Maternity Cohort. (2020) (10)
- Why follow‐back studies should be interpreted cautiously: The case of an HPV‐negative cervical lesion (2016) (10)
- NordScreen - An Interactive Tool for Presenting Cervical Cancer Screening Indicators in the Nordic Countries (2018) (10)
- Human papillomavirus genotype-specific risks for cervical intraepithelial lesions (2020) (10)
- Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions. (1997) (10)
- Risk of invasive cervical cancer in relation to clinical investigation and treatment after abnormal cytology: A population‐based case–control study (2011) (10)
- Human Papillomavirus Infection Determines Prognosis in Cervical Cancer (2022) (10)
- Pseudovirion-binding and neutralizing antibodies to cutaneous human papillomaviruses (HPV) correlated with the presence of HPV DNA in skin. (2013) (9)
- Corrigendum: Detection of DNA viruses in prostate cancer (2016) (9)
- Increase of cervical cancer incidence in Sweden in relation to screening history: population cohort study (2020) (9)
- A systematic review of convalescent plasma treatment for COVID19 (2020) (9)
- Human papillomavirus types in cervical high‐grade lesions or cancer among Nordic women—Potential for prevention (2019) (9)
- Toward "serolomics": papillomavirus serology is taking a technologic lead in high-throughput multiplexed antibody analysis. (2005) (9)
- Association of Short-term Air Pollution Exposure With SARS-CoV-2 Infection Among Young Adults in Sweden (2022) (9)
- Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study (2016) (9)
- Epstein-Barr virus (EBV) antigen-specific leukocyte migration inhibition (LMI) in infectious mononucleosis (IM). I. Kinetics and response to a membrane protein on EBV-transformed cells. (1986) (8)
- Antibodies to SARS-CoV-2 and risk of past or future sick leave (2021) (8)
- High amounts of SARS-CoV-2 precede sickness among asymptomatic healthcare workers (2021) (8)
- The Epstein-Barr virus determined nuclear antigen is composed of at least three different antigens. (1986) (8)
- Differences in transcriptional activity of cutaneous human papillomaviruses. (2008) (8)
- HPV Types in Cervical Precancer by HIV Status and Birth Region: A Population-Based Register Study (2020) (8)
- Bioinformatics for Viral Metagenomics (2013) (8)
- Differing Age-Specific Cervical Cancer Incidence Between Different Types of Human Papillomavirus: Implications for Predicting the Impact of Elimination Programs (2020) (8)
- Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening (2020) (8)
- Early detection and prevention (2019) (8)
- Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study (2018) (8)
- Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial (2022) (8)
- [Condyloma typing important for follow up of HPV vaccination. A condyloma reporting project]. (2008) (7)
- Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination (2017) (7)
- Antibodies against Kaposi sarcoma-associated herpes virus (KSHV) complement control protein (KCP) in infected individuals. (2007) (7)
- Determinants of the presence of human papillomaviruses in the anal canal of Russian men (2018) (7)
- Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type (2015) (7)
- Cervical Cytology Biobanking in Europe (2010) (7)
- Distribution of HPV Genotypes Differs Depending on Behavioural Factors among Young Women (2021) (7)
- Serological responses to human papillomavirus type 16 antigens in women before and after renal transplantation (1993) (7)
- Interactive effect of genetic susceptibility with height, body mass index, and hormone replacement therapy on the risk of breast cancer (2012) (7)
- The 2019 HPV Labnet international proficiency study: Need of global Human Papillomavirus Proficiency Testing. (2021) (7)
- Mutations in human papillomavirus type 16 L1 hypervariable surface-exposed loops affect L2 binding and DNA encapsidation. (2013) (6)
- The process of moving from a regionally based cervical cytology biobank to a national infrastructure. (2015) (6)
- A complex intervention for workflow enhancement at the Swedish cervical cytology biobank. (2014) (6)
- International Quality Assurance of Human Papillomavirus Testing (2008) (6)
- Chlamydia trachomatis infection is a risk factor for cervical cancer (2000) (6)
- Seroconversion to islet autoantibodies between early pregnancy and delivery in non-diabetic mothers. (2011) (6)
- Effect of naturally acquired type-specific serum antibodies against human papillomavirus type 16 infection. (2017) (6)
- Viruses in case series of tumors: Consistent presence in different cancers in the same subject (2017) (6)
- Regular Disappearance of the Human Papillomavirus Genome After Conization of Cervical Dysplasia by Carbon Dioxide Laser (2001) (6)
- Strengthening prevention programs to eliminate cervical cancer in the Nordic countries (2008) (6)
- Characterization of two novel cutaneous human papillomaviruses , HPV 93 and HPV 96 (2007) (6)
- Estimating total excess mortality during a COVID-19 outbreak in Stockholm, Sweden (2020) (6)
- A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets (2022) (6)
- Prospects for accelerated elimination of cervical cancer. (2021) (6)
- Can cervical cancer screening programs be improved by incorporating screening for human papillomavirus infection (1998) (6)
- HPV transcription in skin tumors (2019) (6)
- Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study (2004) (6)
- Elimination of HPV-associated oropharyngeal cancers in Nordic countries. (2021) (6)
- Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial (2021) (6)
- Prevalence of antibodies against Kaposi's sarcoma associated herpes virus (KSHV) complement inhibitory protein (KCP) in KSHV-related diseases and their correlation with clinical parameters. (2011) (5)
- The HPV16 genome is stable in women who progress to in situ or invasive cervical cancer: a prospective population-based study. (2019) (5)
- No evidence of HPV in epidemic and endemic Kaposi's sarcoma. (1993) (5)
- Transcription of human papillomaviruses in nonmelanoma skin cancers of the immunosuppressed (2021) (5)
- Performance Indicators in Breast Cancer Screening in the European Union: A Comparison Across Countries of Screen Positivity and Detection Rates. (2020) (5)
- Fewer than three doses of HPV vaccine. (2015) (5)
- The Antibody Response to Human Papillomavirus (1991) (5)
- Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women (2019) (5)
- Sourcing of the WHO human papillomavirus type 18 international standards for HPV antibody levels. (2016) (5)
- HPV-based screening for prevention of invasive cervical cancer – Authors' reply (2014) (5)
- False-positive prostate cancer markers in a man with symptomatic urethral Chlamydia trachomatis infection (2013) (5)
- Detection of adeno-associated virus type 2 genome in cervical carcinoma (2006) (5)
- Assessing the risk of cervical neoplasia in the post‐HPV vaccination era (2022) (4)
- Are twenty human papillomavirus types causing cervical cancer? (2014) (4)
- Organized primary human papillomavirus–based cervical screening: A randomized healthcare policy trial (2021) (4)
- Seropositivity to Multiple Anogenital Human Papillomavirus (HPV) Types Is Associated With Current Anogenital HPV Infection, Abnormal Cytology, and Seropositivity for Nongenital HPVs (2018) (4)
- Cervical Cancer Screening by Human Papillomavirus Testing Followed by Cytology Triage (2017) (4)
- Antibodies in human sera against the Epstein-Barr virus encoded latent membrane protein (LMP). (1988) (4)
- Exposure to polychlorinated compounds and cryptorchidism; A nested case-control study (2020) (4)
- Antibody responses to defined epitopes in the Epstein-Barr virus BZLF1-encoded transactivator protein among human immunodeficiency virus-infected patients (1996) (4)
- Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial (2021) (4)
- Risk for SARS-CoV-2 infection in healthcare workers outside hospitals: A real-life immuno-virological study during the first wave of the COVID-19 epidemic (2021) (4)
- Comparison of DNA and RNA sequencing of total nucleic acids from human cervix for metagenomics (2021) (4)
- Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial (2022) (4)
- International Journal of Cancer: Editorial (2009) (4)
- Human Papillomavirus Serology Among Women Living With HIV: Type-Specific Seroprevalence, Seroconversion, and Risk of Cervical Reinfection (2018) (4)
- [The new biobank law accepted: a unique chance of improvement]. (2002) (4)
- Evaluation of human papillomavirus DNA detection in samples obtained for routine Chlamydia trachomatis screening. (2015) (4)
- Tumor Necrosis Factor a-11 and DR 15-DQ 6 ( B * 0602 ) Haplotype Increase the Risk for Cervical Intraepithelial Neoplasia in Human Papillomavirus 16 Seropositive Women in Northern Sweden 1 (2000) (4)
- A two-site enzyme immunoassay for quantitation of human papillomavirus type 16 particles. (1995) (3)
- Probabilistic approaches for classifying highly variable anti-SARS-CoV-2 antibody responses (2020) (3)
- Misclassifications in human papillomavirus databases. (2021) (3)
- EUROCOURSE: towards optimisation of the use of cancer registries for scientific excellence in cancer research in Europe: an FP7 ERA-net project (2009) (3)
- [The survey of Danish biobanks suggests a "drop-out" registry]. (2002) (3)
- The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer (2022) (3)
- Drug-induced tumor-specific cytotoxicity in a whole tissue ex vivo model of human pancreatic ductal adenocarcinoma (2022) (3)
- SARS‐CoV‐2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden (2021) (3)
- Estimating effectiveness of HPV vaccination against HPV infection from post-vaccination data in the absence of baseline data. (2018) (3)
- Probabilistic classification of anti‐SARS‐CoV‐2 antibody responses improves seroprevalence estimates (2022) (3)
- Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening (2020) (3)
- Pseudovirion-binding and neutralizing antibodies to cutaneous Human Papillomaviruses correlated to presence of HPV DNA in skin. (2013) (3)
- Human exposome assessment platform (2021) (3)
- Antibodies to SARS-CoV-2 and risk of future sickness (2020) (3)
- Longitudinal biobanks-based study on the joint effects of infections, nutrition and hormones on risk of prostate cancer (2016) (3)
- Validity of maternal genotypes in DNA from archival pregnancy serum samples. (2009) (3)
- Annika with Kaposi ' s Sarcoma Immunodeficiency Virus-Infected Patients Peripheral Blood of Human Viral Load of Human Herpesvirus 8 in (2001) (2)
- Metabolism of 25‐hydroxyvitamin D3 may explain the u‐shaped risk curve for prostate cancer (2004) (2)
- Epstein-Barr virus (EBV) antigen-specific leukocyte migration inhibition in infectious mononucleosis. II. Kinetics of sensitization against five EBV-encoded nuclear proteins and the latent membrane protein. (1989) (2)
- The 2011 HPV LabNet International Proficiency Study (2013) (2)
- [Cervix cancer screening can be cost-effective. Combination of vaginal smears and the HPV test should be even more beneficial]. (2005) (2)
- Severe features during outbreak but low mortality observed immediately before and after a March–May 2020 COVID-19 outbreak in Stockholm, Sweden (2021) (2)
- A prospective study of the correlation between prediagnostic human papillomavirus seropositivity and HPV DNA presence in subsequently occurring cervical cancers (2003) (2)
- HPV‐Positive Status Is an Independent Factor Associated With Sinonasal Inverted Papilloma Recurrence (2021) (2)
- Merkel Cell Polyomavirus: Epidemiology and Clinical Features of Related Cancer (2014) (2)
- Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. (2011) (2)
- IgG Antibodies to Human Papillomavirus Type 16 and Serum Retinol May Jointly Protect Against Cervical Neoplasia (1994) (2)
- Characterization of humoral immune responses against p16 in HPV-associated and non HPV-associated disease (2008) (2)
- [Sexuality and STD infections among teenage girls. "Unprotected sex" is common in spite of sufficient knowledge about the risks]. (1997) (2)
- The WID‐EC test for the detection and risk prediction of endometrial cancer (2022) (2)
- Antibody responses to SARS-CoV-2 train machine learning to assign likelihood of past infection during virus emergence in Sweden (2020) (2)
- Corrigendum to “Vaginal self-sampling without preservative for human papillomavirus testing shows good sensitivity” [J. Clin. Virol. 56 (2013) 52–56] (2013) (2)
- Human papillomavirus load and genotype analysis improves the prediction of invasive cervical cancer (2021) (2)
- Linear epitopes of the replication-activator protein of Epstein-Barr virus recognised by specific serum IgG in nasopharyngeal carcinoma (1995) (2)
- IPVS policy statement on HPV nucleic acid testing guidance for those utilising/considering HPV as primary precancer screening: Quality assurance and quality control issues. (2022) (2)
- Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program (2021) (2)
- Prostate Cancer Risk and Serologic Evidence of Human Papilloma Virus Infection (2003) (2)
- Comparable strategies needed to evaluate human papillomavirus vaccine efficiency across Europe. (2006) (2)
- Nonvaccine human papillomavirus genotype common in women with HIV failing cervical precancer treatment (2021) (2)
- Validation of the cobas 6800 human papillomavirus test in primary cervical screening (2021) (2)
- Screening for high amounts of SARS-CoV-2 identifies pre-symptomatic subjects among healthy healthcare workers (2020) (2)
- SARS-CoV-2 infections among personnel providing home care services for the elderly in Stockholm, Sweden (2020) (2)
- A Population-Based Study of Human Papillomavirus Deoxyribonucleic Acid Testing for Predicting Cervical Intraepithelial Neoplasia (1999) (2)
- Viremia preceding multiple sclerosis: Two nested case-control studies. (2018) (2)
- Epstein-Barr virus gene expression during primary B-lymphocyte infection, in transformed and Burkitt lymphoma-derived cell lines. (1986) (2)
- Human papillomavirus genotype and prognosis of invasive cervical cancer: A nationwide cohort study. (2019) (2)
- Potential SARS-CoV-2 infectiousness among asymptomatic healthcare workers (2021) (2)
- Machine Learning for detection of viral sequences in human metagenomic datasets (2018) (2)
- Human Papillomavirus (HPV) seroprevalence, cervical HPV prevalence, genotype distribution and cytological lesions in solid organ transplant recipients and immunocompetent women in Sao Paulo, Brazil (2022) (2)
- Human papillomavirus seroprevalence and seroconversion among men living with HIV: Cohort study in South Africa. (2020) (1)
- Editorial (2009) (1)
- 44. Detection of the human papillomavirus infection (HPV) on the internationally used environmental surfaces: ready for a ‘take-off’? (2013) (1)
- Screening for Cervical Cancer (2012) (1)
- Cervical cancer screening improvements with self- sampling during the COVID-19 pandemic (2022) (1)
- Erratum: Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study (British Journal of Cancer (2002) 87 (61-64) doi: 10.1038/sj.bjc.6600350) (2004) (1)
- The Use of Antibodies against Synthetic Peptides for Studying the EBV Nuclear Antigen (1985) (1)
- Stratifying Cervical Cancer Risk with Registry Data (2018) (1)
- Comparison of cytology and human papillomavirus-based primary testing in cervical screening programs in the Nordic countries (2021) (1)
- 43. Anal human papillomavirus prevalence in HIV-negative and HIV-infected Russian men who have sex with women (2013) (1)
- HPV Vaccination and the Risk of Invasive Cervical Cancer (2021) (1)
- Prevalence of antibodies against Kaposi's sarcoma associated herpes virus (KSHV) complement inhibitory protein (KCP) in KSHV-related diseases and their correlation with clinical parameters (2011) (1)
- Response to the author: invitation to cancer screening: putting the car before the horse? (2019) (1)
- SARS-CoV-2 Infections Among Healthcare Workers Outside Hospitals (2021) (1)
- Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study (2022) (1)
- Nationwide Rereview of Normal Cervical Cytologies before High-Grade Cervical Lesions or before Invasive Cervical Cancer (2021) (1)
- Author's reply to: Human papillomavirus type 197 is not associated with skin tumors (2019) (1)
- FAST TRACK EUROGIN 2008 roadmap on cervical cancer prevention (2009) (1)
- [Swedish consensus on cervix cancer vaccination. Vaccination programs for eradication of HPV16/18 should be initiated in elementary schools]. (2006) (1)
- HPV type replacement in the post-vaccination era (2006) (1)
- Genetic predisposition, parity, age at first childbirth and risk for breast cancer (2012) (1)
- Serological Responses toPapillomavirus Group-Specific Antigens in WomenwithNeoplasia oftheCervix Uteri (1990) (1)
- Atypical glandular cells and development of cervical cancer: Population‐based cohort study (2022) (1)
- WHO HPV LabNet-Newsletter 05 WHO HPV LabNet World Health Organization ’ s Global Human Papillomavirus ( HPV ) Laboratory Network (2007) (1)
- [How to handle biological material? New legislation concerning biobanks in Finland]. (2001) (1)
- Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC) (2020) (1)
- Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses (2022) (1)
- Convalescent plasma for treatment of COVID-19: study protocol for an open randomised controlled trial in Sweden (2021) (1)
- Rapid Communication Human papillomavirus subtypes are not uncommon (2007) (1)
- Estimating COVID-19 contribution to total excess mortality (2020) (1)
- Induction of Broadly Cross-neutralizing Antisera against Mucosal and Cutaneous Human Papillomayiruses (HPV) by HPV16L1-16L2 Virus-like Particles (RG1-VLP) (2010) (0)
- Serum testosterone, sex hormone binding globulin and prostate cancer risk. A Nordic nested case-control study (2004) (0)
- 976 H. pylori Seropositivity Before Age 40 and Subsequent Risk of Stomach Cancer: A Glimpse of the True Relationship? (2009) (0)
- Author's reply to: Implementation and organization of cancer screening in France (2018) (0)
- Human Papillomavirus Types in Invasive Cervical Cancer in Relation to Cervical Screening (2022) (0)
- Multiplex detection of human herpesviruses from archival specimens using MALDI-TOF mass spectrometry (2007) (0)
- Contents Vol. 81, 2014 (2015) (0)
- HPV-based screening for prevention of invasive cervical cancer Reply (2014) (0)
- Viral infections and Cancer (2010) (0)
- Chlamydia trachomatis and cervical squamous cell carcinoma (Letter, in reply) (2001) (0)
- A pilot study of risk-stratified cervical cancer screening (2021) (0)
- A NESTED CASE-CONTROL STUDY OF INTRAUTERINE EXPOSURE TO PERSISTENT ORGANOCHLORINE POLLUTANTS IN RELATION TO RISK OF HYPOSPADIA (2011) (0)
- Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study (2018) (0)
- Genome-wide transcriptome profiling of ex-vivo precision-cut slices from human pancreatic ductal adenocarcinoma (2020) (0)
- Immunogenicity and Safety Results Comparing Single Dose Human Papillomavirus Vaccine with Two or Three Doses in Tanzanian Girls - the DoRIS Randomised Trial (2022) (0)
- To the editor: Chlamydia trachomatis and cervical cancer (2001) (0)
- HPV 16-Derived Synthetic Peptides with Ability to Upregulate MHC Class I Expression on RMA-S or T2 Cells, as Detected by Enzyme Immunoassay (1994) (0)
- Professor Geo von Krogh (2010) (0)
- Professor Geo von Krogh Obituary (2010) (0)
- Both high and low level of vitamin D are associated with a higher prostate cancer risk. A prediagnostic study in stored sera (2004) (0)
- Near full control of human papillomavirus vaccine types. (2015) (0)
- Exploration of Patient-Derived Pancreatic Ductal Adenocarcinoma Ex Vivo Tissue for Treatment Response (2023) (0)
- Current opinions on papillomaviruses (1994) (0)
- Process for the human papillomavirus (HPV) detection for diagnostic use (1991) (0)
- Prospective StudyofHPV16Viral LoadandRiskofInSituand Invasive Squamous Cervical Cancer (2013) (0)
- Antibodies to the latent human papillomavirus proteins, diagnostic systems and diagnostic methods (1989) (0)
- Maternal smoking during pregnancy, and testicular cancer in the offspring (2008) (0)
- P3.002 Detection of Human Papillomavirus (HPV) Infection in Anal Samples in Russian Men Who Have Sex with Women (MSW) (2013) (0)
- A novel human in vitro papillomavirus type 16 positive tonsil cancer cell line with high sensitivity to radiation and cisplatin (2019) (0)
- Overtreatment rate after immediate local excision of suspected cervical intraepithelial neoplasia: A prospective cohort study. (2022) (0)
- Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. (Corr. 2004;91(6):1226) (2002) (0)
- Proceedings of the HPV vaccination workshop: vaccinating women against premature death. (2000) (0)
- Some clear answers regarding transmission of genital human papillomavirus. (2019) (0)
- Abstract II: No difference in JCV or BKV seroprevalence between colon cancer patients and controls (2005) (0)
- Vaccinating women against premature death: summary of an International Workshop, Helsinki, Finland, 10.01.2000. (2001) (0)
- Author's reply to: Cancer screening policy in Hungary (2018) (0)
- [Evaluable implementation of HPV testing]. (2013) (0)
- Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study (2019) (0)
- Authors' reply. (2020) (0)
- Creating personas for exposome research: the experience from the HEAP project (2023) (0)
- Abstract I: Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles (2005) (0)
- Risk of invasive cervical cancer in relation to cytologic results in the screening history : a population‐based case‐control study (2011) (0)
- Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer (2018) (0)
- Antibody to human papillomavirus latent protein, diagnostic system and its use (1989) (0)
- NFKK meeting - Biobanks (2002) (0)
- Evidence of Association between Prostate Cancer and Infection with Herpes Simplex Virus Type 2 or Human Herpesvirus Type 8 : A Nested Case-Control Study (2005) (0)
- Polypeptides which react with antibodies against latent human papillomavirus proteins, antibodies reactive with polype (1989) (0)
- leukoencephalopathy? for elevated risk of progressive multifocal treated with immunosuppression: can we screen JC viral loads in patients with Crohn's disease (2008) (0)
- To the editor: Human papillomavirus infection as a risk factor for squamous cell carcinoma of the head and neck (2001) (0)
- P1137 Human papillomavirus infection and risk of in situ and invasive cervical adenocarcinoma (2009) (0)
- Decoding our environment: The European Human Exposome Network (2021) (0)
- Evaluation of co-testing with cytology and human papillomavirus testing in cervical screening. (2022) (0)
- Antibodies against latent proteins of human papillomavirus, diagnostic systems and methods. (1989) (0)
- Comparison of Immune Responses after One Dose of HPV Vaccine in a Dose-Reduction HPV Vaccine Trial in Adolescent Girls in Tanzania to the Costa Rica Vaccine and India HPV Vaccine Trials (2022) (0)
- O16.6 Pre-Vaccination Seroprevalence of 15 Human Papillomavirus (HPV) Types Among Slovenian Women Screened For Cervical Cancer (2013) (0)
- 237 Post-vaccination HPV surveillance (2009) (0)
- Human papillomavirus self‐sampling with mRNA testing benefits routine screening (2022) (0)
- Monoclonal antibodies against human papillomavirus E7 oncoprotein for diagnosis of cervical neoplasia and cancer (2012) (0)
- WITHDRAWAL—Administrative Duplicate Publication: The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention Europe (2019) (0)
- Quality assurance in human papillomavirus testing for primary cervical screening (2023) (0)
- Faculty Opinions recommendation of Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. (2019) (0)
- Population-Based Human Papillomavirus Serosurvey Reveals HPV16/18 Herd Effect But No Clear Type-Replacement in Unvaccinated Females 6 Years Post Gender-Neutral Vaccination in a Cluster Randomised Trial (2019) (0)
- HPV seroprevalence and seroconversion among women living with HIV-1 : cohort study in South Africa. (2017) (0)
- Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening (2020) (0)
- P825 HPV seroprevalence and seroconversion among HIV-positive men: cohort study in south africa (2019) (0)
- [Testing HPV vaccine is an ethical dilemma. Can we afford not to offer vaccination against an infection which is a cause of cancer?]. (2003) (0)
- Is the elimination of cervical cancer now 3 times easier? One-dose vaccine efficacy has far-reaching implications (2022) (0)
- HPV‐induced host epigenetic reprogramming is lost upon progression to high‐grade cervical intraepithelial neoplasia (2023) (0)
- Roadmap for a precision-medicine initiative in the Nordic region (2019) (0)
- Antigenic andImmunogenic Epitopes SharedbyHuman Papillomavirus Type16andBovine, Canine, and AvianPapillomaviruses (1991) (0)
- Human Papillomavirus (HPV) 26 and HPV 88 replicate to extremely high levels in squamous cell carcinomas (SCC) of the nail unit in anHIV-immunosuppressed patient (2008) (0)
- Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model (2014) (0)
- LBP-1.07 Ecology of Human papillomavirus (HPV) infections in the male, studied using Expressed Prostate Secretions (EPS) (2011) (0)
- In Vivo and In Vitro Intragenomic Rearrangement of TT Viruses (cid:1) (2007) (0)
- Impact of HPV vaccination on cervical screening performance: a population-based cohort study (2020) (0)
- Extremely high viral loads of HPV26 and HPV88 in squamous cell carcinomas (SCC) of the nail unit in an HIV-immunosuppressed patient (2008) (0)
- Shared environment and colorectal cancer: A Nordic pedigree registry‐based cohort study (2022) (0)
- DNA methylation-based detection and prediction of cervical intraepithelial neoplasia grade 3 and invasive cervical cancer with the WID™-qCIN test (2022) (0)
- Predicting past and future SARS-CoV-2-related sick leave using discrete time Markov modelling (2022) (0)
- P2-164 Human papillomavirus, other sexually transmitted infections and risk of cervical cancer. A Nordic Joint Study (2011) (0)
- [Experts: Good evidence for screening recommendations]. (2015) (0)
- Chapter 5. Evaluation of durability of protection of HPV prophylactic vaccines (2014) (0)
- Latent protein antibodies of human papillomavirus, diagnostic systems and procedures. (1989) (0)
- Prevalence of Antibodies Against Defined HPV Epitopes Among Incident Cases of Cervical Neoplasia: Current Status and Concepts (1994) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Joakim Dillner?
Joakim Dillner is affiliated with the following schools: